Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
3.0
Journals
CIMB
Special Issues
Intestinal Inflammation: From Molecular Mechanisms to Therapeutic Strategies
cimb-logo
Submit to Special Issue Submit Abstract to Special Issue Review for CIMB Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Intestinal Inflammation: From Molecular Mechanisms to Therapeutic Strategies

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 2152

Special Issue Editors

Dr. Raffaele Pellegrino

E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy
Interests: inflammatory bowel diseases; Crohn’s disease; ulcerative colitis; inflammation; gastrointestinal endoscopy
Special Issues, Collections and Topics in MDPI journals
Dr. Antonietta Gerarda Gravina

E-Mail Website
Guest Editor
Division of Hepatogastroenterology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy
Interests: inflammatory bowel disease; digestive endoscopy; Crohn's Disease; ulcerative colitis; inflammation; celiac disease; biologics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Intestinal inflammation, a hallmark of disorders such as inflammatory bowel disease (IBD), celiac disease, and other gastrointestinal conditions, arises from a complex interplay of genetic, environmental, microbial, and immunological factors. Recent advances in molecular biology and immunology have illuminated the intricate pathways driving intestinal inflammation, including dysregulated immune responses, gut barrier dysfunction, and microbiota imbalances. These insights are paving the way for novel therapeutic strategies, from targeted molecular interventions to microbiome-based therapies.

This Special Issue, "Intestinal Inflammation: From Molecular Mechanisms to Therapeutic Strategies", aims to bring together cutting-edge research exploring the underlying molecular mechanisms of intestinal inflammation and innovative approaches to its treatment. We welcome original research, reviews, and clinical studies addressing topics such as immune regulation, epithelial barrier repair, microbial–host interactions, and the development of novel anti-inflammatory agents. We seek to advance our understanding and improve outcomes for patients with intestinal inflammatory disorders.

Dr. Raffaele Pellegrino
Dr. Antonietta Gerarda Gravina
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • celiac disease
  • Crohn's Disease
  • ulcerative colitis
  • colitis
  • hemorrhoidal disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 7672 KiB  
Article
Molecular Subtypes and Biomarkers of Ulcerative Colitis Revealed by Sphingolipid Metabolism-Related Genes: Insights from Machine Learning and Molecular Dynamics
by Quanwei Li, Junchen Li, Shuyuan Liu, Yunshu Zhang, Jifeng Liu, Xing Wan and Guogang Liang
Curr. Issues Mol. Biol. 2025, 47(8), 616; https://doi.org/10.3390/cimb47080616 - 4 Aug 2025
Viewed by 301
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with disrupted lipid metabolism. This study aimed to uncover novel molecular subtypes and biomarkers by integrating sphingolipid metabolism-related genes (SMGs) with machine learning approaches. Using data from the GEO and GeneCards databases, 29 [...] Read more.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with disrupted lipid metabolism. This study aimed to uncover novel molecular subtypes and biomarkers by integrating sphingolipid metabolism-related genes (SMGs) with machine learning approaches. Using data from the GEO and GeneCards databases, 29 UC-related SMGs were identified. Consensus clustering was employed to define distinct molecular subtypes of UC, and a diagnostic model was developed through various machine learning algorithms. Further analyses—including functional enrichment, transcription factor prediction, single-cell localization, potential drug screening, molecular docking, and molecular dynamics simulations—were conducted to investigate the underlying mechanisms and therapeutic prospects of the identified genes in UC. The analysis revealed two molecular subtypes of UC: C1 (metabolically dysregulated) and C2 (immune-enriched). A diagnostic model based on three key genes demonstrated high accuracy in both the training and validation cohorts. Moreover, the transcription factor FOXA2 was predicted to regulate the expression of all three genes simultaneously. Notably, mebendazole and NVP-TAE226 emerged as promising therapeutic agents for UC. In conclusion, SMGs are integral to UC molecular subtyping and immune microenvironment modulation, presenting a novel framework for precision diagnosis and targeted treatment of UC. Full article
(This article belongs to the Special Issue Intestinal Inflammation: From Molecular Mechanisms to Therapeutic Strategies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 635 KiB  
Review
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review
by Antonietta Gerarda Gravina, Raffaele Pellegrino, Michele Izzo, Ilaria De Costanzo, Giuseppe Imperio, Fabio Landa, Assunta Tambaro and Alessandro Federico
Curr. Issues Mol. Biol. 2025, 47(5), 383; https://doi.org/10.3390/cimb47050383 - 21 May 2025
Cited by 1 | Viewed by 1528
Abstract
Inflammatory bowel diseases (IBDs) are complex immune-mediated disorders characterised by an unpredictable direction and commonly associated metabolic comorbidities along with obesity and type 2 diabetes mellitus (T2DM). Recent evidence has highlighted the therapeutic capacity of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), already [...] Read more.
Inflammatory bowel diseases (IBDs) are complex immune-mediated disorders characterised by an unpredictable direction and commonly associated metabolic comorbidities along with obesity and type 2 diabetes mellitus (T2DM). Recent evidence has highlighted the therapeutic capacity of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), already employed in treating T2DM and obesity, in modulating systemic and intestinal inflammatory responses. This narrative review examines the general organic traits of GLP-1, with a specific awareness of its primary gastrointestinal actions and the efficacy of GLP-1 RAs in promoting weight loss and dealing with glycaemic control, mainly in sufferers with IBD. Furthermore, the effects of those agonists on the progression of IBD, their protection profile, their impact on bowel preparation for endoscopic procedures, and their therapeutic capacity, supported through preclinical and early clinical studies, are discussed. GLP-1 RAs appear to lessen the intestinal inflammatory burden by enhancing intestinal epithelial barrier features and modulating the gut microbiota. However, further clinical research will be necessary to verify whether GLP-1 RAs could play a position in IBD treatment. Full article
(This article belongs to the Special Issue Intestinal Inflammation: From Molecular Mechanisms to Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop